Immunotherapy

Which Combination Immunotherapies to Use, and When? High Response Rates, but Serious Toxicity Remains a Concern

Chase Doyle

February 2018, Vol 9, No 1 | Payers’ Perspectives In Oncology: ASH 2017 Highlights - Immunotherapy

Atlanta, GA—As single-agent immunotherapies continue to show promising results, the challenge is now to determine which combination regimens with immunotherapies can improve outcomes. According to data presented at ASH 2017, 3 approaches are currently being explored. [ Read More ]

Novel TKI Leads to Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia

Wayne Kuznar

February 2018, Vol 9, No 1 | Payers’ Perspectives In Oncology: ASH 2017 Highlights - Immunotherapy

Atlanta, GA—A novel, third-generation, oral tyrosine kinase inhibitor (TKI), PF-114 mesylate, has antileukemic activity in heavily pretreated patients with chronic myeloid leukemia (CML), including those with T315I mutation, said Jorge E. Cortes, MD, Deputy Chair, Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, at ASH 2017. [ Read More ]

CAR T-Cell Therapy Shows “Impressive” Results in Multiple Myeloma

Wayne Kuznar

February 2018, Vol 9, No 1 | Payers’ Perspectives In Oncology: ASH 2017 Highlights - Immunotherapy, Multiple Myeloma

Atlanta, GA—Although chimeric antigen receptor (CAR) T-cell therapies directed against the CD19 protein garnered much attention at ASH 2017, CAR T-cells targeting B-cell maturation antigen (BCMA), a protein expressed nearly universally on multiple myeloma cells, were found to be remarkably effective in patients with heavily pretreated multiple myeloma. [ Read More ]

CAR T-Cell Therapy Makes Significant Inroads in Lymphoma: Kymriah and Yescarta Show Durable Remissions

Phoebe Starr

February 2018, Vol 9, No 1 | Payers’ Perspectives In Oncology: ASH 2017 Highlights - Immunotherapy

Atlanta, GA—CD19-directed chimeric antigen receptor (CAR) T-cell therapy continues to show excellent and durable responses in patients with lymphoma who have no other treatment options. Two studies presented at ASH 2017 provide encouraging news for 2 new drugs, including long-term follow-up of the pivotal ZUMA-1 study of the CAR T-cell therapy axicabtagene ciloleucel (Yescarta), and primary results from the JULIET study of tisagenlecleucel (Kymriah). [ Read More ]

Extended Follow-Up Confirms Survival Benefit with Pembrolizumab in Urothelial Cancer

Charles Bankhead

Immunotherapy

Chicago, IL—Treatment with the PD-1 inhibitor pembrolizumab (Keytruda) significantly prolonged overall survival (OS) compared with chemotherapy in patients with advanced urothelial carcinoma that progressed during or after first-line chemotherapy, said Dean F. Bajorin, MD, FACP, FASCO, Medical Oncologist and Frederick R. Adler Senior Faculty Chair, Memorial Sloan Kettering Cancer Center, New York City, at the 2017 ASCO annual meeting. [ Read More ]

When Does Immunotherapy Work Best in Lung Cancer?

Wayne Kuznar

Immunotherapy, Lung Cancer

Chicago, IL—Response to immunotherapy in non–small-cell lung cancer (NSCLC) differs depending on the driver mutation involved and on the amount of PD-L1 expression within the tumor. Immune checkpoint inhibitors in NSCLC—PD-1 and PD-L1 inhibitors—have similar efficacy and adverse event profiles. These were among the topics discussed at the 2017 ASCO annual meeting in a session on immunotherapy and lung cancer. [ Read More ]

Checkpoint Inhibitors Show Promise in Patients with Mesothelioma

Phoebe Starr

August 2017, Vol 8, No 4 | Payers’ Perspectives In Oncology: ASCO 2017 Highlights - Immunotherapy

Chicago, IL—Immunotherapy holds promise as second-line or third-line treatment of patients with malignant pleural mesothelioma, a rare cancer with increasing incidence. Early findings from the ongoing, phase 2 MAPS-2 clinical trial showed that immunotherapy slowed the growth of malignant pleural mesothelioma after relapse, reported lead investigator Arnaud Scherpereel, MD, PhD, Head, Pulmonary and Thoracic Oncology Department, University Hospital of Lille, France, at the 2017 ASCO annual meeting. MAPS-2 is the largest clinical trial to date of immune checkpoint inhibitor therapy in patients with malignant pleural mesothelioma. [ Read More ]